Anti-GPC3 CAR T for Recurrent or Refractory Lung Squamous Cell Carcinoma
Status:
Unknown status
Trial end date:
2019-04-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to observe and confirm the safety, tolerance and cell
pharmacokinetics of lentivirus-transduced CAR-GPC3 T cells (CAR-GPC3 T cells targeting GPC3)